gptkbp:instance_of
|
gptkb:drug
|
gptkbp:bfsLayer
|
6
|
gptkbp:bfsParent
|
gptkb:Valeant_Pharmaceuticals
|
gptkbp:approves
|
gptkb:FDA
|
gptkbp:average_temperature
|
room temperature
|
gptkbp:class
|
immune response modifier
|
gptkbp:clinical_trial
|
gptkb:unknown
Phase III
dermatology
long-term safety studies
studied in various populations
comparative studies with other treatments
efficacy in different skin types
|
gptkbp:contraindication
|
open wounds
sunburned skin
hypersensitivity to imiquimod
|
gptkbp:dosage_form
|
gptkb:skincare_product
|
gptkbp:duration
|
up to 16 weeks
|
gptkbp:education
|
wash hands after application
apply to affected area only
avoid sun exposure during treatment
do not cover with bandage
|
gptkbp:effective_date
|
gptkb:1997
|
gptkbp:excretion
|
urine
|
gptkbp:form
|
gptkb:skincare_product
|
gptkbp:frequency
|
once daily
|
https://www.w3.org/2000/01/rdf-schema#label
|
Aldara
|
gptkbp:indication
|
gptkb:actinic_keratosis
gptkb:superficial_basal_cell_carcinoma
external genital warts
|
gptkbp:ingredients
|
gptkb:imiquimod
|
gptkbp:interacts_with
|
none significant
|
gptkbp:invention
|
patented
|
gptkbp:is_atype_of
|
D06 B B03
|
gptkbp:is_available_on
|
generic version
|
gptkbp:is_used_for
|
treating genital warts
treating actinic keratosis
|
gptkbp:lifespan
|
gptkb:unknown
|
gptkbp:manager
|
topical
|
gptkbp:manufacturer
|
gptkb:3_M
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
gptkbp:metabolism
|
liver
|
gptkbp:packaging
|
single-use packets
|
gptkbp:population
|
gptkb:Person
adults
|
gptkbp:provides_information_on
|
used in combination with other therapies
|
gptkbp:requires
|
gptkb:theorem
|
gptkbp:research_focus
|
viral infections
skin cancer treatment
immune modulation
|
gptkbp:safety_features
|
Category B
|
gptkbp:side_effect
|
skin irritation
swelling
redness
itching
burning sensation
scabbing
|
gptkbp:social_structure
|
C14 H16 N4 O4 S
|
gptkbp:traded_on
|
gptkb:Aldara
|